Quantcast
Last updated on April 24, 2014 at 11:16 EDT

PanGenex (PGXC) Begins International Distribution and Welcomes Dr. Jimmy Diaz As International Product Liaison

September 16, 2008

PanGenex Corporation (Pink Sheets:PGXC) is pleased to welcome Jimmy Diaz M.D. to the position of International Product Liaison. Dr. Diaz is an Internal Medicine Physician practicing in Kingsland, Georgia. With his vast experience and international presence, Dr. Diaz’s main responsibility is to develop international markets and facilitate PanGenex expansion worldwide. Dr. Diaz will begin to market in Puerto Rico to a number of different outlets, including but not limited to pharmacies, physicians and other distributors. Dr. Diaz is also scheduled to present at the Puerto Rico Health Conference in October, and has planned distribution trips to Europe later this year to reach his contacts in Spain and other parts of the European Union.

Dr. Diaz graduated from St. John Baptist Medical School in Puerto Rico in 1980. He specialized in Internal Medicine at the Sound Shore Medical Center in New York. He began practicing Internal Medicine in Atlanta, Georgia and now continues in Kingsland, Georgia. Dr. Diaz is an International Lecturer for VAX-D Medical Technologies and has participated in seminars, the training of physicians and technicians and currently lectures in Spain, Italy, Greece, Argentina, Puerto Rico, Dominican Republic and the United States.

In addition to the relationship with Dr. Diaz, distribution partner Medivisor, Inc. (Pink Sheets: MVSR – News) reported in a press release today that the all-natural cholesterol lowering product LIPIDEME(TM) is gaining interest in Italy. Medivisor is currently in negotiations with Italian distributors for sale of LIPIDEME(TM).

“We are very pleased that as interest in LIPIDEME(TM) and our other products grow we are able to develop relationships that will allow our product lines to cross borders and have an impact in the lifestyles of people around the globe,” states Jeff Roman, President and CEO of PanGenex Corporation. “I expect to be able to announce more distribution updates throughout this week.”

About PanGenex Corporation:

PanGenex is a publicly traded corporation (PINK SHEETS:PGXC) and pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.

Disclaimer:

Cautionary Statement about Forward-Looking Statements

This press release contains “forward-looking statements,” which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as “expects,”"anticipates,”"intends,”"plans,”"believes,”"seeks” or “will.” Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things: (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.